{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-071251","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.000887+00:00","generated_at":"2026-06-26T23:58:00.229999+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galera Q4/2021 net loss $16.8M; positive Phase 3 ROMAN trial, cash $71M","bullets":["Net loss of $16.8M ($0.64/sh) in Q4 2021 vs $20.1M ($0.80/sh) in Q4 2020; FY net loss $80.5M ($3.12/sh).","Phase 3 ROMAN trial of avasopasem met primary endpoint (SOM incidence); plans to meet FDA in 2022 for NDA submission.","Cash, cash equivalents & short-term investments $71.2M at Dec 31, 2021; expected runway into 2H 2023.","Topline data from AESOP (esophagitis) and GRECO-1 (lung cancer) both expected in 1H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-071251","json":"https://secwatch.observer/filing/0001193125-22-071251.json","markdown":"https://secwatch.observer/filing/0001193125-22-071251.md","text":"https://secwatch.observer/filing/0001193125-22-071251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/0001193125-22-071251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522071251/d310055d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:58:00.229999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}